Physician profile
James Macdonald
NPI 1922000264
$673.92
in general payments reported to CMS, 2019-2025
15 companies · $18.46 in 2025
The $18.46 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $180 · 2021: $234 · 2022: $17.01 · 2024: $15.41 · 2025: $18.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $107.09 | 2020 | |
| Amgen INC. | $97.23 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.92 | 2019-2021 | |
| Boston Scientific Corporation | $55.67 | 2020-2024 | Advantage System |
| Pfizer INC. | $54.39 | 2019-2021 | |
| Myovant Sciences INC. | $51.00 | 2021 | |
| Janssen Biotech, INC. | $42.91 | 2019 | |
| Coloplast Corp | $42.78 | 2020-2022 | |
| Abbvie INC. | $33.91 | 2021-2025 | |
| Rochester Medical Corporation | $31.75 | 2021 | |
| Astellas Pharma US INC | $24.67 | 2019-2021 | |
| 180 Medical, INC. | $20.11 | 2021 | |
| Dendreon Pharmaceuticals LLC | $19.79 | 2019 | |
| Merck Sharp & Dohme LLC | $18.94 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.